Early evidence suggests omalizumab could help people with alpha-gal syndrome by reducing the frequency or severity of allergic reactions to red meat, according to findings presented at a major allergy conference.
In a study shared Thursday at the annual meeting of the American College of Allergy, Asthma and Immunology, researchers reported that 95% of 64 participants with confirmed diagnoses experienced meaningful improvement while taking omalizumab for an average of 23 months. The analysis has not yet been published in a peer-reviewed journal.
How omalizumab may aid alpha-gal syndrome
Alpha-gal syndrome is largely linked to bites from the lone star tick. When the tick feeds on mammals such as cows, deer, pigs, and goats, it can acquire a sugar molecule known as alpha gal.
A subsequent bite to a person can transfer that molecule, which in some individuals triggers an allergy to red meat and, in some cases, gelatin and dairy.
Symptoms vary widely, from hives and severe abdominal pain to potentially life-threatening anaphylaxis. Physicians typically advise strict avoidance of red meat and meat-based broths and gravies, and may recommend avoiding gelatin or dairy depending on sensitivity.
Omalizumab, sold under the brand name Xolair, is already approved for severe food allergies including peanut, egg, and dairy. The treatment targets immunoglobulin E, or IgE, the antibody that drives allergic responses, and removes it from the bloodstream.
As one allergy specialist explained, lowering IgE raises the amount of allergen needed to provoke a reaction.
Experts emphasized that omalizumab does not cure food allergies. Patients still need to avoid trigger foods.
The medication is intended to serve as a protective layer, lowering the risk that an accidental exposure will lead to a severe event.
Patient experience and expert caution
A Virginia resident diagnosed with alpha-gal syndrome in 2019 said she has seen substantial improvement after a year on omalizumab for other food allergies. After accidentally consuming dairy, she reported only mild stomach pain rather than anaphylaxis.
The study’s lead investigator, an allergy and immunology fellow at the University of North Carolina at Chapel Hill, said the findings suggest omalizumab may offer an additional option for patients who continue to have reactions despite careful avoidance.
Specialists not involved in the research described the data as encouraging while cautioning against using the drug to enable routine consumption of red meat. They noted that omalizumab is costly and should be used primarily to reduce life-threatening risk.
Eight participants in the analysis were able to reintroduce red meat to their diets. The research team urged caution in interpreting this, noting that alpha-gal IgE levels can decline naturally over time.
It remains unclear whether omalizumab increased reaction thresholds, facilitated reintroduction as sensitivity waned, or both. The study did not test whether tolerance persisted after stopping the drug.
Calls for clinical trials and targeted use
Another expert, a professor of allergy and systems biology in New York City, said the results came from a retrospective analysis and called for a prospective clinical trial to evaluate whether the drug reduces sensitivity to red meat.
The UNC researcher agreed that a trial is needed to identify which patients benefit most and to establish optimal duration and dosing. However, recruiting could be difficult because participants would likely need to undergo monitored food challenges involving red meat and remain under observation for many hours.
In the interim, some clinicians suggest considering omalizumab on a temporary basis for patients with severe reactions, particularly when blood tests show very high levels of IgE antibodies against alpha gal.
Alpha-gal syndrome on the rise
Clinicians report seeing more cases as tick ranges shift in the United States. A recent analysis by the Centers for Disease Control and Prevention estimated that 24% of adults in five states where lone star ticks are prevalent had antibodies to alpha gal, indicating exposure.
Specialists said what was once concentrated in the South and Southeast is now appearing more broadly. They advise patients to prioritize tick bite prevention to reduce the likelihood of additional exposures, which can worsen or prolong sensitivity.
Lone star ticks are most active in late spring, early summer, and early fall.
Experts recommend using tick repellents on skin and clothing during outdoor activities that may involve exposure, including walking in wooded areas, mowing lawns, golfing, or hiking, especially where small rodents and deer are present.
For people navigating severe dietary restrictions, stories about free food deals and restaurant offerings can also carry added practical considerations.